Skip to main content
Print

Anti-angiogenic ophthalmic agents

What are Anti-angiogenic ophthalmic agents?

Anti-angiogenic ophthalmic agents act as vascular endothelial growth factor (VEGF) antagonists. When retinal pigment cells become ischemic and dry up VEGF stimulates generation of new blood vessels by a process called neovascularization. During the generation of new blood vessels in the retina, if the blood vessels do not generate properly it causes leaking. This can lead to loss of vision.

Anti-angiogenic ophthalmic agents are used to stop neovascularization in age related macular degeneration.

List of Anti-angiogenic ophthalmic agents

View by  Brand | Generic
Drug Name Avg. Rating Reviews
Eylea (Pro)
Generic name: aflibercept
7.0
 50 reviews
Lucentis (Pro)
Generic name: ranibizumab
6.5
 15 reviews
Vabysmo (Pro)
Generic name: faricimab
8.4
 5 reviews
Beovu (Pro)
Generic name: brolucizumab
7.0
 3 reviews
Macugen (Pro)
Generic name: pegaptanib
9.0
 1 review
Susvimo (Pro)
Generic name: ranibizumab 		No reviews
Cimerli (Pro)
Generic name: ranibizumab 		No reviews
Byooviz (Pro)
Generic name: ranibizumab 		No reviews
For ratings, users were asked how effective they found the medicine while considering positive/adverse effects and ease of use (1 = not effective, 10 = most effective).

See also

Medical conditions associated with anti-angiogenic ophthalmic agents:

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer